Stockreport

Aktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519 and Provides Business Updates and Full Year 2025 Financial Results

Aktis Oncology, Inc. - Common stock  (AKTS) 
NASDAQ:AMEX Investor Relations: ir.akoustis.com
PDF Progressing vision to expand the reach of targeted radiopharmaceuticals to large patient populationsAnticipating multiple milestones in the next 12 months, including ini [Read more]